log in
Print | Back

Walder Wyss Ltd.

Andreas Wildi

Andreas Wildi

Partner

Expertise

  • Healthcare & Life Science
  • Regulatory
  • Healthcare & Life Sciences

WSG Practice Industries

Activity

WSG Leadership

Life Sciences Group
Member

Walder Wyss Ltd.
Switzerland

Profile
Andreas Wildi, born in 1972, is a medical doctor and an attorney at law. He consults and represents Dow Jones and Nasdaq listed multinational companies as well as mid- and small cap enterprises in the Life Sciences sector. He mainly focuses on Swiss and international reimbursement & pricing law of pharmaceuticals and other therapeutic products. Regulatory issues of pharmaceuticals, medical devices, special nutrition, cosmetics, genetic testing, stem cell- and blood products are his further key areas of practise.

Andreas Wildi studied medicine at the University of Zurich and graduated as medical doctor (MD). Working part-time in hospital, GP-practice and on international rescue missions, he completed his law degree at the University of St. Gallen HSG (MLaw). Before passing the bar exam, he gained his first professional legal experience as clerk with the Cantonal Court of Schaffhausen and with a recognised business law firm in Zurich. From his first position as an attorney at law in a large Zurich business law firm, Andreas Wildi was asked to work for the Swiss Government, where he led the pharmaceutical reimbursement & pricing unit in the Federal Office of Public Health. Thereafter, Andreas Wildi broadened his market access expertise internationally, as EMEA market access law director for Janssen Pharmaceuticals (Johnson & Johnson). Since 2012, he has built up his legal practise in a large, well accepted Zurich business law firm. In 2015, Walder Wyss elected Andreas Wildi as their partner.

Andreas Wildi works in German, French and English. He is admitted to all Swiss Courts and guest lecturer on pharmaceutical law at the University of Lucerne’s Faculty of Law.
Areas of Practice

Healthcare & Life Science | Healthcare & Life Sciences | Regulatory

Articles

Court Annuls FOPH Order Limiting Medicinal Product Price Increase
Walder Wyss Ltd., December 2019

On 7 August 2019 the Federal Administrative Court annulled a Federal Office of Public Health (FOPH) order that had limited the price increase of a medicinal product on the list of specialities to two years. The product manufacturer had requested a price increase under Article 67(2) of the Healthcare Insurance Ordinance (SR 832.102), having incurred higher costs following the loss of two suppliers...

Additional Articles


Arzneimittel sind kein knappes Gut
by Andreas Wildi
in: "Neue Zürcher Zeitung" 23 June 2018


Limitierung von Arzneimitteln im Krankenversicherungsrecht: Wo wird die Grenze zur Rationierung überschritten?
by Bernhard Rütsche and Andreas Wildi
in: "Recht 2016" 4/2016, pp. 199–212


Schränken hohe Arzneimittelpreise die ärztliche Therapiefreiheit ein?
by Andreas Wildi
in: "Fachzeitschrift Rheuma Schweiz" 1/2016, pp. 39–41


Vertragshandbuch Pharma und Life Sciences – Besonderheiten des Schweizer Rechts, 10. Kapitel
co-authored by Simon Holzer, Michael Ritscher and Andreas Wildi
2015, pp. 959 ff


Ärztliche Freiheit trotz Kontraindikationen?
by Andreas Wildi
in: "Rheuma Schweiz" 6/2015, pp. 36–38


Nebenwirkungen des Bundesratsenscheids, Kommentar in der NZZ zu Änderungen der Schweizer Arzneimittelpreisfestsetzung
by Andreas Wildi
in: "Neue Zürcher Zeitung (NZZ)" 125/2015, p. 19


Eine Wegleitung für die medizinische und pharmazeutische Praxis sowie für Behörden und Versicherer
co-authored by Max Giger, Urs Saxer, Andreas Wildi and Markus B. Fritz
in: Verlagsforum Gesundheitswesen (Editor[s]), "Arzneimittelrecht"
Zurich 2013


WSG's members are independent firms and are not affiliated in the joint practice of professional services. Each member exercises its own individual judgments on all client matters.

HOME | SITE MAP | GLANCE | PRIVACY POLICY | DISCLAIMER |  © World Services Group, 2020